Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
ConditionParkinson Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-99
SponsorUniversity Hospital Schleswig-Holstein
About this trial
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age between 50 and 99
Disqualifiers
Presence of clinical PD at the time of study inclusion
Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
Trial population
General population
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionNo intervention
Treatment groups
2,000 Participants
are divided into 2 treatment groupsGroup A: REM behavior disorder +1 intervention
Group B: REM behavior disorder -1 intervention
Trial outcomes
Primary outcomes
1
Risk marker profile
Extend and progression of risk marker profile
Time frame
Analysis after three years.Secondary outcomes
1
Non-motor and motor symptoms
Development and progression of non-motor and motor symptoms
Time frame
Analysis after three yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital Schleswig-Holstein
Lead sponsor
UCB Biopharma SRL
Collaborator
University of Kiel
Collaborator
Source ClinicalTrials.gov